Bronchiectasis Adult Clinical Trial
Official title:
Efficacy and Safety of tobRamycin Inhalation Solution for Pseudomonas AeruginoSa Eradication in Bronchiectasis (ERASE): Study Protocol for a Multi-center, 2×2 Factorial Randomized, Double-blind, Placebo-controlled Trial
People with bronchiectasis are prone to Pseudomonas aeruginosa (PA) infections, which can become chronic and lead to increased death rates and disease severity. Studies from cystic fibrosis suggest that eradication therapy aimed at PA can successfully transition patients to a culture-negative status, providing long-term benefits. Current guidelines for managing bronchiectasis in adults recommend eradicating PA when it is first or newly isolated; however, there is a lack of randomized controlled trials supporting such recommendations. The researchers hypothesize that both oral ciprofloxacin combined with Tobramycin inhalation solution and Tobramycin inhalation solution alone are superior to no eradication (inhaled saline) in terms of the eradication rates of PA, defined as a negative sputum culture of PA at both 24 weeks and 36 weeks.
The presence of Pseudomonas aeruginosa (PA) in bronchiectasis patients is associated with a greater impairment in lung function, increased systemic and airway inflammation, more frequent exacerbations, decreased quality of life, a higher risk of hospitalization, and increased mortality. Current guidelines recommend eradicating PA when it is first isolated, but there is limited randomized controlled trial evidence to support this. In cystic fibrosis, early infection with PA is clearly linked to worse outcomes, and eradication is associated with clinical benefits, including improved lung function and reduced hospitalization. Small sample observational studies have shown that eradication therapy following initial PA isolation is efficient, with eradication rates of 40%-57% in bronchiectasis. Therefore, a randomized control trial of PA eradication therapy is needed to determine the microbiological and clinical outcomes of this therapy. There is also uncertainty about whether inhaled antibiotics alone are sufficient to eradicate PA in non-cystic fibrosis bronchiectasis, given the less severe nature of the disease compared to cystic fibrosis. It's unclear whether adding another antibiotic, such as oral ciprofloxacin in this study, to inhaled antibiotics at the initial stage is necessary as an enhanced treatment for eradicating PA in bronchiectasis. To address these knowledge gaps, a multicenter, 2×2 factorial randomized, double-blind, placebo-controlled, parallel-group study is designed in bronchiectasis patients with newly or firstly isolated PA. This study aims to investigate the efficacy and safety of tobramycin inhalation solution alone or in combination with oral ciprofloxacin in eradicating PA in bronchiectasis. Patients will be randomly assigned to one of four groups: 1. Placebo group: participants will receive inhaled saline twice daily for 12 weeks and an oral ciprofloxacin placebo twice daily for 2 weeks. 2. Oral ciprofloxacin alone group: participants will receive 750mg of oral ciprofloxacin twice daily for 2 weeks and inhaled saline twice daily for 12 weeks. 3. Tobramycin inhalation solution alone group: participants will receive 300mg of inhaled tobramycin twice daily for 12 weeks and an oral ciprofloxacin placebo twice daily for 2 weeks. 4. Combination group: participants will receive 300mg of inhaled tobramycin solution twice daily for 12 weeks and 750mg of oral ciprofloxacin twice daily for 2 weeks. This study will provide valuable insights into the most effective treatment strategy for eradicating PA in bronchiectasis patients. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04142827 -
The Effect of Long Term Therapy With High Flow Humidification Compared to Usual Care in Patients With Bronchiectasis (BX)
|
N/A | |
Recruiting |
NCT06393257 -
Airway Clearance Technique of Oscillation and Lung Expansion in Bronchiectasis
|
N/A | |
Not yet recruiting |
NCT04509661 -
Efficacy and Safety of Inhaled Bronchodilator in Non-CF Bronchiectasis With Airflow Limitation
|
Phase 4 | |
Recruiting |
NCT06017739 -
Expiratory Flow Accelerator (Efa) vs Efa + High Flow in Chronic COPD and Bronchiectasis
|
N/A | |
Completed |
NCT04435327 -
Lung Damage Caused by SARS-CoV-2 Pneumonia (COVID-19)
|
||
Recruiting |
NCT03715322 -
Tobramycin in Bronchiectasis Colonized With Pseudmonas Aeruginosa
|
Phase 3 | |
Recruiting |
NCT03696290 -
Value of Inhaled Treatment With Aztreonam Lysine in Bronchiectasis
|
Phase 2 | |
Not yet recruiting |
NCT05068518 -
The Role of Airway Microbiota on Clinical Phenotypes and Disease Severity in Bronchiectasis
|
||
Recruiting |
NCT04658277 -
Effect of Long Term Clarithromycin for Prevention of Exacerbations in Non-cystic Fibrosis Bronchiectasis in Asian Populations
|
N/A | |
Completed |
NCT04744220 -
Evaluation of the Effect of Yoga Training on Functional Capacity and Quality of Life in Patients With Bronchiectasis
|
N/A | |
Completed |
NCT05764343 -
The Effect of Immediate Smoking Cessation Interventions for Smokers With Chronic Airway Diseases
|
N/A | |
Recruiting |
NCT05582798 -
Bronchiectasis Alpha-1 Augmentation Trial- Modulating Airway Neutrophil Function
|
Phase 4 | |
Not yet recruiting |
NCT04987827 -
Investigating the Clinical Features and Prognosis of Bronchiectasis Adult Patients
|
||
Recruiting |
NCT03791086 -
The BRIDGE Study - Bronchiectasis Research Involving Databases, Genomics and Endotyping
|
||
Completed |
NCT04234789 -
Predictors of Physical Activity Performance and Dynamic Hyperinflation in Patients With Bronchiectasis
|
N/A | |
Recruiting |
NCT04865861 -
The Characteristic of Airway Microbiome Profiling of COPD-bronchiectasis Overlap Patients and Its Association With Acute Exacerbation
|
||
Completed |
NCT04742270 -
Home Airway Clearance in Patients With Bronchiectasis (Home-Care Bronchiectasis)
|
N/A | |
Recruiting |
NCT05330637 -
Study on the Influence of Climatic and Environmental Factors on Respiratory Diseases in Sanya, Hainan Province, China.
|
||
Completed |
NCT05989360 -
The Utility of Lung Clearance Index in Ethnic Groups and in Disease
|
N/A | |
Completed |
NCT03125174 -
Characterization of Airway Mucus in Bronchiectasis Patients and Healthy Controls
|
N/A |